Table 4.
Association of IL2RA mRNA expression with prognosis relevant variables in CBF, intermediate-risk and poor-risk AML
| CBF AML | Intermediate-risk AML | Poor-risk AML | |||||||
|---|---|---|---|---|---|---|---|---|---|
| High IL2RA mRNA | Low IL2RA mRNA | p-value | High IL2RA mRNA | Low IL2RA mRNA | p-value | High IL2RA mRNA | Low IL2RA mRNA | p-value | |
| Age group | 0.026 | 0.813 | 0.348 | ||||||
| 15–29 | 5 (9) | 16 (45) | 8 (30) | 26 (118) | 1 (9) | 9 (28) | |||
| 30–49 | 1 (9) | 25 (45) | 15 (30) | 59 (118) | 3 (9) | 10 (28) | |||
| 50–65 | 3 (9) | 4 (45) | 7 (30) | 33 (118) | 5 (9) | 9 (28) | |||
| High WBC counts | 2 (8) | 12 (30) | 0.686 | 9 (18) | 29 (78) | 0.423 | 1 (9) | 5 (23) | 0.648 |
| High blast percentage | 5 (9) | 32 (45) | 0.439 | 18 (30) | 72 (118) | 1.000 | 3 (9) | 19 (28) | 0.118 |
| Secondary AML | 0 (9) | 0 (45) | NA | 1/30 | 2/118 | 0.496 | 2/9 | 3 (28) | 0.577 |
| FLT3-ITD+ | 2 (7) | 0 (36) | 0.023 | 17 (27) | 14 (90) | < 0.001 | 2 (7) | 3 (25) | 0.296 |
| NPM1+ | 0 (7) | 0 (36) | NA | 8 (27) | 28 (90) | 1.000 | 0 (7) | 0 (25) | NA |
| NPM1+FLT3-ITD− | 0 (7) | 0 (36) | NA | 0 (27) | 22 (90) | 0.002 | 0 (7) | 0 (25) | NA |
| CEBPADM+ | 0 (7) | 0 (36) | NA | 1 (27) | 18 (90) | 0.070 | 0 (7) | 0 (25) | NA |
| c-Kit D816V+ | 1 (7) | 4 (36) | 1.000 | 0 (27) | 1 (90) | 1.000 | 0 (7) | 1 (25) | 1.000 |
The number in the parentheses is the number of patients that are of high or low IL2RA expression tested in that particular parameter
NA not applicable
*The p value for RFS and OS is calculated by Kaplan–Meier log-rank test. The p value for the other parameters are calculated by Fisher’s exact test or Chi-Square test